J01GB06 amikacin
ATC group of level 5 – chemical substance · in plain English: antibiotics
This site has the patient leaflet or the SPC of 7 medicines in this group.
- 2 prescription only (POM)
Active substance: Amikacin – all medicines with this substance, also in combinations.
Place in the ATC classification
- J Antiinfectives for systemic use 1,393 medicines
- J01 Antibacterials for systemic use 668 medicines
- J01G Aminoglycoside antibacterials 25 medicines
- J01GB Other aminoglycosides 25 medicines
- J01GB06 amikacin 7 medicines
- J01GB Other aminoglycosides 25 medicines
- J01G Aminoglycoside antibacterials 25 medicines
- J01 Antibacterials for systemic use 668 medicines
Medicines
| Medicine | Legal category |
|---|---|
| Amikacin 125 mg/ml solution for injection/infusion SPC | – |
| Amikacin 250 mg / ml injection SPC | – |
| Amikacin 250 mg / ml solution for injection/infusion SPC | Prescription only (POM) |
| Amikacin 250 mg/ml solution for injection or infusion SPC | – |
| Amikacin Kabi 5 mg/ml solution for infusion SPC | – |
| Amikin injection 100 mg / 2 ml SPC | Prescription only (POM) |
| Arikayce liposomal 590 mg nebuliser Dispersion SPC | – |
Other groups of the same level
- J01GB01 tobramycin 8 medicines
- J01GB03 gentamicin 10 medicines
Other names of the ATC group
- Czech: J01GB06 Amikacin
- French: J01GB06 amikacine
- German: J01GB06 Amikacin
- Spanish: J01GB06 AMIKACINA
- German: J01GB06 Amikacin
- Italian: J01GB06 AMIKACINA
- Polish: J01GB06 AMIKACYNA
- Turkish: J01GB06 amikasin
- Portuguese (Brazil): J01GB06 Amicacina
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group J01GB06
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.
